Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials

Summary

This meta-analysis assessed the efficacy and safety of single-agent versus dual immunotherapy for metastatic colorectal cancer (mCRC) with DNA mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). PD-1/PD-L1 monotherapy significantly improved objective response rate (ORR) compared to chemotherapy, demonstrating a favorable safety profile. Dual immunotherapy (nivolumab plus ipilimumab) showed a superior ORR over monotherapy, but with increased toxicity. Benefits in progression-free survival (PFS) and overall survival (OS) were not consistently statistically significant across trials.

Critical appraisal

This meta-analysis provides crucial data for clinical decision-making in the treatment of dMMR/MSI-H mCRC, confirming the superior efficacy of immune checkpoint inhibitors over chemotherapy and highlighting the importance of dMMR/MSI-H status testing. The study underscores a trade-off between the increased efficacy of dual immunotherapy and its higher toxicity risk, necessitating a personalized risk-benefit assessment for each patient. The findings also suggest the need for further research into biomarkers to better select patients and optimize therapeutic strategies.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology